exp3174 has been researched along with alpha-naphthoflavone in 1 studies
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (alpha-naphthoflavone) | Trials (alpha-naphthoflavone) | Recent Studies (post-2010) (alpha-naphthoflavone) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 665 | 1 | 142 |
| Protein | Taxonomy | exp3174 (IC50) | alpha-naphthoflavone (IC50) |
|---|---|---|---|
| Carboxylic ester hydrolase | Sus scrofa (pig) | 0.0478 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 2.3034 | |
| Cytochrome P450 1A1 | Homo sapiens (human) | 0.1921 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.1698 | |
| Aromatase | Homo sapiens (human) | 1.035 | |
| Substance-K receptor | Homo sapiens (human) | 5.8471 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.01 | |
| Thromboxane-A synthase | Homo sapiens (human) | 6.7608 | |
| Adenosine receptor A1 | Homo sapiens (human) | 1.1325 | |
| Aryl hydrocarbon receptor | Mus musculus (house mouse) | 0.025 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.05 | |
| DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | 4.98 | |
| Cytochrome P450 1B1 | Homo sapiens (human) | 0.0449 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.355 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guengerich, FP; Jeong, HG; Lee, H; Lee, HS; Rho, JK; Yun, CH | 1 |
1 other study(ies) available for exp3174 and alpha-naphthoflavone
| Article | Year |
|---|---|
Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzoflavones; Biotransformation; Biphenyl Compounds; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Imidazoles; Losartan; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Receptors, Angiotensin; Tetrazoles | 1995 |